Lutetium-177 DOTATATE therapy for neuroendocrine tumor

Lutetium-177 DOTATATE therapy for neuroendocrine tumor

What is Lutetium-177 Dotate Therapy?

Lutetium-177 (Lu-177) dotate therapy is a targeted radionuclide therapy emerging as a powerful tool for treating gastroenteropancreatic neuroendocrine tumors (NETs). NETs are slow-growing tumors arising from hormone-producing cells in the digestive system and other parts of the body.

Who is it For?

Lutetium-177 dotate therapy may be considered for patients with:

How it Works?

The Next Generation Technology is Here at Kiran PET CT - GE-DISCOVERY IQ GEN 2

Discovery IQ Gen 2 is the smartest choice for ensuring better outcomes through true discovery

Why Choose Us

Discover the future of healthcare at Kiran Nuclear Medicine and PET CT Center. Our pioneering theranostics approach not only diagnoses but also tailors treatment plans specific to your needs, ensuring precise and effective care. Experience the power of personalized medicine with us.
Radioactive iodine therapy

Pioneering Theranostics

At Kiran Nuclear Medicine and PET CT Center, we're leading the way in theranostics, integrating advanced diagnostics with personalized treatment plans.

Radioactive iodine therapy

Precision and Effectiveness

Our commitment to theranostics means that you receive precise diagnoses and targeted therapies, leading to more effective treatment outcomes. We leverage cutting-edge technology and expertise to deliver the highest standard of care.

Radioactive iodine therapy

Personalized Medicine

We prioritize your individual health needs, providing customized treatment plans that consider your medical history, preferences, and treatment goals.

Meet Our Doctors

Dr Kiran Kumar JK

Dr Kiran Kumar JK

Founder and Director MBBS, MD(PGIMER)
Dr Manoj Devanathan

Dr Manoj Devanathan

Medical Director MBBS, MD(JIPMER)
Dr Abhiram GA

Dr Abhiram GA


Frequently asked questions

What is Lutetium-177 Dotatate Therapy?

Lutetium-177 Dotatate Therapy, also known as Peptide Receptor Radionuclide Therapy (PRRT), is a targeted treatment used primarily for neuroendocrine tumors (NETs) that express somatostatin receptors. It involves the administration of a radioactive isotope, Lutetium-177, coupled with a somatostatin analogue peptide called Dotatate. This combination allows for the selective delivery of radiation to NET cells.

How does Lutetium-177 Dotatate Therapy work?

Somatostatin receptors are overexpressed on the surface of neuroendocrine tumor cells. Dotatate is a molecule that binds specifically to these receptors. When coupled with Lutetium-177, a beta-emitting radionuclide, Dotatate acts as a carrier to deliver radiation directly to the tumor cells. The radiation emitted by Lutetium-177 damages the tumor cells, leading to their destruction.

Who is a candidate for Lutetium-177 Dotatate Therapy?

Lutetium-177 Dotatate Therapy is typically recommended for patients with advanced or metastatic neuroendocrine tumors (NETs) that express somatostatin receptors. It may be considered for patients who have progressive disease despite other treatments or who are not candidates for surgery or other therapies.

Is Lutetium-177 Dotatate Therapy safe?

Lutetium-177 Dotatate Therapy is generally considered safe when administered by trained healthcare professionals in specialized nuclear medicine facilities. However, like any medical treatment, there are potential side effects and risks associated with the therapy, including bone marrow suppression, kidney damage, and radiation exposure to other tissues. Patients will be closely monitored during and after treatment to manage any adverse effects.

What should I expect during Lutetium-177 Dotatate Therapy?

Before undergoing Lutetium-177 Dotatate Therapy, patients may undergo imaging studies such as somatostatin receptor scintigraphy (SRS) or positron emission tomography (PET) scans with somatostatin analogues to assess the extent of disease and somatostatin receptor expression. The therapy itself involves the intravenous administration of Lutetium-177 Dotatate, typically as a series of treatments spaced several weeks apart. Patients may experience side effects such as fatigue, nausea, and decreased blood cell counts, which are usually temporary and manageable.

What are the expected outcomes of Lutetium-177 Dotatate Therapy?

Lutetium-177 Dotatate Therapy has shown promising results in clinical studies, with many patients experiencing tumor shrinkage, symptom relief, and improved quality of life. However, individual responses to the therapy can vary, and not all patients may derive the same benefit. The therapy may also be used in combination with other treatments as part of a comprehensive management plan for neuroendocrine tumors.

Book Your Scan Now

Book Your Scan Now

Banshankari Location

Indira Nagar Location

For Immediate Assistance

Download Catalogue Now

Book Now & Get 20% off On First Visit